Retrospective analysis of hops toxicosis in dogs (2002-2014): 71 cases.
ASPCA
dantrolene
hops
hypermetabolism
hyperthermia
toxicity
Journal
Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)
ISSN: 1476-4431
Titre abrégé: J Vet Emerg Crit Care (San Antonio)
Pays: United States
ID NLM: 101152804
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
16
06
2020
received:
20
04
2020
accepted:
21
07
2020
pubmed:
10
9
2021
medline:
2
2
2022
entrez:
9
9
2021
Statut:
ppublish
Résumé
To describe a population of dogs with hops toxicosis, including clinical signs observed, treatments performed, patient outcome, and overall prognosis. Clinical findings and treatment interventions were evaluated for their potential effects on outcome. This study also aims to review hops toxicosis and treatment options. Retrospective observational study. Poison Control Center. Seventy-one dogs presenting for hops ingestion. None. Records of 71 dogs with known hops ingestion from the ASPCA - Animal Poison Control Center (ASPCA-APCC) database and the Tufts University medical record system were reviewed. Fifty-nine (77%) of the dogs survived. The most common clinical signs on presentation were hyperthermia and tachycardia, with presenting temperatures and heart rates significantly higher in nonsurvivors. There was no significant difference between survivors and nonsurvivors in regard to signalment. Time to presentation was shorter in survivors (5.0 vs 5.5 h; P < 0.0001). The median amount of hops ingested was higher in nonsurvivors (2 vs 2.5 oz; P < 0.0001). Hops ingestion caused hyperthermia in 96% (68/71) of dogs. The median time to death in the nonsurvivor group was 10.7 hours (2-30 h). None of the decontamination, cooling, or treatment measures (dantrolene, cyproheptadine, sedatives) evaluated in this population were associated with improved survival. After adjusting for cooling, time to presentation, and dantrolene administration, every degree of elevation in temperature was associated with a 78% increased chance of death. All dogs that survived to discharge had complete resolution of clinical signs. Hops toxicosis can result in significant hyperthermia, tachypnea, and tachycardia. Seventy-seven percent of dogs survived with intensive treatment. Continued education of the potential for hops toxicosis is advised.
Substances chimiques
Hypnotics and Sedatives
0
Types de publication
Journal Article
Observational Study, Veterinary
Langues
eng
Sous-ensembles de citation
IM
Pagination
90-97Informations de copyright
© Veterinary Emergency and Critical Care Society 2021.
Références
Claflin J. Toxicology brief: hops make dogs hot. Vet Tech. 2013;34(8).
Hare WR. Hops. In: Plumlee KH, ed. St. Louis, MO: Mosby; 2004:430-431.
Duncan KL, Hare WR, Buck WB. Malignant hyperthermia-like reaction secondary to ingestion of hops in five dogs. J Am Vet Med Assoc. 1997;210(1):51-54.
Brunson DB, Hogan KJ. Malignant hyperthermia: a syndrome not a disease. Veterinary Clinic of North America: Small Animal Practice. Philadelphia, PA: Elsevier; 2004:1419-1433.
Adami C, Axiak S, Raith K, et al. Unusual perianesthetic malignant hyperthermia in a dog. J Am Vet Med Assoc. 2012;240(4):450-453.
Chohan AS, Greene SA. Anesthesia case of the month. Malignant hyperthermia. J Am Vet Med Assoc. 2011;239(7):936-940.
Bellah JR, Robertson SA, Buergelt CD, et al. Suspected malignant hyperthermia after halothane anesthesia in a cat. Vet Surg. 1989;18:483-488.
Kirmayer AH, Klide AM, Purvance JE. Malignant hyperthermia in a dog: case report and review of the syndrome. J Am Vet Med Assoc. 1984;185(9):978-982.
Nelson TE. Malignant hyperthermia in dogs. J Am Vet Med Assoc. 1991;198(6):989-994.
Rand JS, O'Brien PJ. Exercise-induced malignant hyperthermia in an English springer spaniel. J Am Vet Med Assoc. 1987;190(8):1013-1014.
Dickinson PJ, Sullivan M. Exercise induced hyperthermia in a racing greyhound. Vet Rec. 1994;135(21):508.
hyperthermi KDCM, a. Korean J Anesthesiol. 2012;63(5):391-401.
O'Brien PJ, Cribb PH, White RJ, et al. Canine malignant hyperthermia: diagnosis of susceptibility in a breeding colony. Can Vet J. 1983;24(6):172-177.
Roberts MC, Mickelson JR, Patterson EE, et al. Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1). Anesthesiology. 2001;95(3):716-725.
Rosenberg H, Davis M, James D, et al. Malignant hyperthermia. Orphanet J Rare Dis. 2007;2:21.
Correia AC, Silva PC, da Silva BA. Malignant hyperthermia: clinical and molecular aspects. Rev Bras Anestesiol. 2012;62(6):820-837.
Bandschapp O, Girard T. Malignant hyperthermia. Swiss Med Wkly. 2012, 142.
Wang G, Tian L, Aziz N, et al. Terpene biosynthesis in glandular trichomes of hop. Plant Physiol. 2008;148(3):1254-1266.
Gros J, Peeters F, Collin S. Occurrence of odorant polyfunctional thiols in beers hopped with different cultivars. First evidence of an S-cysteine conjugate in hop (Humulus lupulus L.). J Agric Food Chem. 2012;60(32):7805-7816.
Karabín M, Hudcová T, Jelínek L, et al. Biologically active compounds from hops and prospects for their use. Compr Rev Food Sci Food Saf. 2016;15(3):542-567.
Cribb PH, Olfert EA, Reynolds FB. Erythrocyte osmotic fragility testing and the prediction of canine malignant hyperthermia susceptibility. Can Vet J. 1986;27(12):517-522.
O'Brien PJ, Forsyth GW, Olexson DW, et al. Canine malignant hyperthermia susceptibility: erythrocytic defects-osmotic fragility, glucose-6-phosphate dehydrogenase deficiency and abnormal Ca2+ homeostasis. Can J Comp Med. 1984;48(4):381-389.
O'Brien PJ, Pook HA, Klip A, et al. Canine stress syndrome/malignant hyperthermia susceptibility: calcium-homeostasis defect in muscle and lymphocytes. Res Vet Sci. 1990;48(1):124-128.
Malignant hyperthermia. Generatio GmbH/Center for Animal Genetics. Available from: https://www.centerforanimalgenetics.com/services/dog-genetic-testing/hereditary-disease-testing-for-dogs/malignant-hyperthermia/ Accessed Aug 23, 2021.
Malignant hyperthermia (MH). Animal Genetics. Available from https://www.animalgenetics.us/canine/Genetic_Disease/MH.asp. Accessed Aug 23, 2021.
Nelson TE, Lin M, Zapata-Sudo G, et al. Dantrolene sodium can increase or attenuate activity of skeletal muscle ryanodine receptor calcium release channel. Clinical implications. Anesthesiology. 1996;84(6):1368-1379.
Ratto D, Joyner RW. Treasure Island, FL: StatPearls Publishing; 2021. https://www.ncbi.nlm.nih.gov/books/NBK535398/#_NBK535398_pubdet. Accessed Aug 23.
Haraschak JL, Langston VC, Wang R, et al. Pharmacokinetic evaluation of oral dantrolene in the dog. J Vet Pharmacol Ther. 2014;37(3):286-294.
Veterinary Partner [Internet]. Veterinary Information Network. Methocarbamol (Robaxin-V); 2002. Available from : https://veterinarypartner.vin.com/default.aspx?pid=19239&catId=102894&id=4951816 Accessed Aug 23, 2021.
Wappler F, Fiege M, Schulte am Esch J. Pathophysiological role of the serotonin system in malignant hyperthermia. Br J Anaesth. 2001;87(5):794-798.
Mills KC. Serotonin syndrome. A clinical update. Crit Care Clin. 1997;13(4):763-783.
Stevens JF, Taylor AW, Clawson JE, et al. Fate of xanthohumol and related prenylflavonoids from hops to beer. J Agric Food Chem. 1999;47(6):2421-2428.
Odunayo A. Management of potassium disorders. Clinician's brief. 2014;5:60-72.
Malowicki MG, Shellhammer TH. Isomerization and degradation kinetics of hop (Humulus lupulus) acids in a model wort-boiling system. J Agric Food Chem. 2005;53(11):4434-4439.
Bernotienė G, Nivinskienė O, Butkienė R, et al. Chemical composition of essential oils of hops (Humulus lupulus L.) growing wild in Aukštaitija. Chemija. 2004;15:31-36.